KeyBanc last night downgraded Harvard Bioscience (HBIO) to Sector Weight from Overweight without a price target Despite the successful launch of the company’s new products such as the MeshMEA organoid platform and a turnaround strategy that continues to take shape, financing risk and an outsized academic market exposure are likely to weigh on shares of Harvard Bioscience over the near-term, the analyst tells investors in a research note. The firm adds that Harvard is currently operating under a waiver from its lenders, following the violation of a consolidated net leverage ratio covenant.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- Harvard Bioscience downgraded to Sector Weight from Overweight at KeyBanc
- Harvard Bioscience price target lowered to $4.50 from $5.50 at Benchmark
- Harvard Bioscience Reports 2024 Financial Results
- Harvard Bioscience Navigates Growth Amid Challenges
- Harvard Bioscience reports Q4 adjusted EPS 6c vs. 4c last year
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue